Evaluation of the desferrithiocin pharmacophores as a vector for hydroxamates

被引:8
作者
Bergeron, RJ [1 ]
McManis, JS
Bussenius, J
Brittenham, GN
Wiegand, J
机构
[1] Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA
[2] Columbia Univ Coll Phys & Surg, Dept Pediat, Div Hematol, New York, NY 10032 USA
关键词
D O I
10.1021/jm980611q
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of (S)-desmethyldesferrithiocin (DMDFT, 1) hydroxamates and a bis-salicyl polyether hydroxamate are evaluated for their iron-clearing properties in rodents; some of these are further assessed in primates. These hydroxamates include (S)-desmethyldesferrithiocin, N-methylhydroxamate (2); (S)-desmethyldesferrithiocin, N-[5-(acetylhydroxyamino)pentyl]hydroxamate (3); desmethyldesferrithiocin, N-benzylhydroxamate (4); (S,S)-N-1, N-8-bis[4,5-dihydro-2-(3-hydroxy-2-pyridinyl)-4-thiazoyl]-N-1,N-8-dihydroxy-3,6-dioxa-1,8-octanediamine (5); and N-1,N-8-bis(2-hydroxybenzoyl)-N-1,N-8-dihydroxy-3,6-dioxa-1,8-octanediamine (6). The ligands are evaluated when given both orally (po) and subcutaneously (sc) in the bile-duct-cannulated rodent model. In iron-overloaded primates, ligands 1-4 are assessed when administered po and sc. The efficiencies of the hydroxamates are shown to vary considerably; giving the compounds sc consistently resulted in greater chelating efficiency in vivo. After oral administration in the primate, compound 3, a pentacoordinate unsymmetrical dihydroxamate, produces iron excretion sufficient to warrant further preclinical evaluation both as a potential orally active iron-chelating agent and as a parenteral iron chelator. The increased iron clearance of several of these ligands when administered sc versus po also underscores the idea that parenteral administration is a reasonable alternative to a less efficient, orally active device which would require large and frequent doses.
引用
收藏
页码:2881 / 2886
页数:6
相关论文
共 13 条
[1]   METAL-COMPLEX FORMATION OF A NEW SIDEROPHORE DESFERRITHIOCIN AND OF 3 RELATED LIGANDS [J].
ANDEREGG, G ;
RABER, M .
JOURNAL OF THE CHEMICAL SOCIETY-CHEMICAL COMMUNICATIONS, 1990, (17) :1194-1196
[2]  
BERGERON RJ, 1990, ANN NY ACAD SCI, V612, P378
[3]  
BERGERON RJ, 1993, BLOOD, V81, P2166
[4]   THE DESFERRITHIOCIN PHARMACOPHORE [J].
BERGERON, RJ ;
LIU, CZ ;
MCMANIS, JS ;
XIA, MXB ;
ALGEE, SE ;
WIEGAND, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (10) :1411-1417
[5]   HBED: A potential alternative to deferoxamine for iron-chelating therapy [J].
Bergeron, RJ ;
Wiegand, J ;
Brittenham, GM .
BLOOD, 1998, 91 (04) :1446-1452
[6]   Synthesis and biological evaluation of naphthyldesferrithiocin iron chelators [J].
Bergeron, RJ ;
Wiegand, J ;
Wollenweber, M ;
McManis, JS ;
Algee, SE ;
RatliffThompson, K .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (08) :1575-1581
[7]   EVALUATION OF DESFERRITHIOCIN AND ITS SYNTHETIC ANALOGS AS ORALLY EFFECTIVE IRON CHELATORS [J].
BERGERON, RJ ;
WIEGAND, J ;
DIONIS, JB ;
EGLIKARMAKKA, M ;
FREI, J ;
HUXLEYTENCER, A ;
PETER, HH .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (07) :2072-2078
[8]   STOFFWECHSELPRODUKTE VON ACTINOMYCETEN .27. UBER DIE KONSTITUTION VON FERRIOXAMIN-B [J].
BICKEL, H ;
HALL, GE ;
KELLERSCHIERLEIN, W ;
PRELOG, V ;
VISCHER, E ;
WETTSTEIN, A .
HELVETICA CHIMICA ACTA, 1960, 43 (07) :2129-2138
[9]   COORDINATION CHEMISTRY OF MICROBIAL IRON TRANSPORT .42. STRUCTURAL AND SPECTROSCOPIC CHARACTERIZATION OF DIASTEREOMERIC CR(III) AND CO(III) COMPLEXES OF DESFERRIFERRITHIOCIN [J].
HAHN, FE ;
MCMURRY, TJ ;
HUGI, A ;
RAYMOND, KN .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1990, 112 (05) :1854-1860
[10]  
LEE P, 1993, DRUG METAB DISPOS, V21, P640